Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 70
Summary
- Conditions
- Cholangiocarcinoma
- Breast Cancer
- Endometrial Cancer
- Gastric Cancer
- Lung Cancer
- MPN
- Multiple Myeloma
- Myeloproliferative Neoplasms
- Solid Tumor
- UC
- Urothelial Cancer
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02393248
- Collaborators
- Not Provided
- Investigators
- Study Director: Luis Féliz, MD Incyte Corporation
Get Well Soon